Aarti Drugs Ltd
NSE:AARTIDRUGS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
321.75
545.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Aarti Drugs Ltd
Operating Income
Aarti Drugs Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
Operating Income
₹2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
6%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹67.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹60.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
20%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹130.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹51.6B
|
CAGR 3-Years
168%
|
CAGR 5-Years
35%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹31.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
Aarti Drugs Ltd
Glance View
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
See Also
What is Aarti Drugs Ltd's Operating Income?
Operating Income
2.5B
INR
Based on the financial report for Sep 30, 2025, Aarti Drugs Ltd's Operating Income amounts to 2.5B INR.
What is Aarti Drugs Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
6%
Over the last year, the Operating Income growth was 8%. The average annual Operating Income growth rates for Aarti Drugs Ltd have been -2% over the past three years , -6% over the past five years , and 6% over the past ten years .